At the American Society of Nephrology (ASN) Kidney Week meeting, an interim analysis of a phase III trial of sibeprenlimab in immunoglobulin A (IgA) nephropathy showed a nearly 50% reduction in ...
A investigator reported that sibeprenlimab halved baseline proteinuria levels over 12 months in trial patients with IgA nephropathy. Sibeprenlimab continues to reduce proteinuria in patients with IgA ...
Researchers report results from a post hoc analysis evaluating the treatment response of sibeprenlimab vs placebo across different proteinuria thresholds in patients with IgA nephropathy.
Patients may self-administer Voyxact after receiving proper training on subcutaneous injection technique. The Food and Drug Administration (FDA) has granted accelerated approval to Voyxact ® ...
Verywell Health on MSN
Proteinuria in complement 3 glomerulopathy: Why it matters and what to do
Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Proteinuria affects most people with complement 3 glomerulopathy ...
Verywell Health on MSN
6 types of treatment for complement 3 glomerulopathy
Medically reviewed by Matthew Wosnitzer, MD Managing complement 3 glomerulopathy involves several treatment options aimed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results